Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai MicroPort MedBot Group Co
Its shares trade on HKEX under the ticker 2252.HK. It has been listed since 2 November 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥551.1m and a net loss of CN¥249.7m. At that date it held total assets of CN¥1.34bn and shareholders' equity of CN¥410.8m.
Shanghai MicroPort MedBot (Group) Co., Ltd. operates as a surgical robot company dedicated to designing, developing and commercializing surgical robots to assist surgeons in performing complex surgical procedures. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2021-11-02. The firm's main business is the design, development and commercialization of innovative surgical robots. The firm's products include Toumai Laparoscopic Surgical Robot, DFVision 3D Electronic Laparoscope and Honghu Orthopedic Surgical Robot. The firm's surgical robots are used in multiple minimally invasive surgery fields, including endoscopic surgery, orthopedic surgery, pan-vascular surgery, natural cavity surgery and percutaneous puncture surgery. In addition, the Company also provides education and training services for its surgical robot MedBot.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 2 Nov 2021
- Employees
- 900
- Website
- medbotsurgical.com ↗
Leadership
Pay as last reported
- Mr. Hongbin SunNon-Executive Chairman of the BoardCN¥4.1m
- Dr. Chao HePresident, Executive Director, since 2017CN¥32.4m
- Mr. Yu LiuSenior Vice President, Chief Commercial Officer
- Ms. Haiying YuSenior Vice President
- Mr. Shuxiang LiVice President - Supply Chain
- Ms. Cong FangExecutive Director, Board Secretary, since 2021
- Ms. Siu Lam YeungCompany Secretary
- Mr. Chen ChenNon-Executive Director
- Mr. Xinxing ChenNon-Executive Director
- Mr. Wai Man ChungIndependent Non-Executive Director
- Dr. Minghua LiNon-Executive Independent DirectorCN¥120,000
- Mr. Haisong YaoNon-Executive Independent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shanghai MicroPort MedBot Group employs 900 skilled employees in Shanghai.
- The company's Toumai Laparoscopic Surgical Robot is used in endoscopic surgery fields.
- DFVision 3D Electronic Laparoscope supports minimally invasive procedures in multiple specialties.
Weaknesses
- The company's IPO date was 2 November 2021, limiting recent market experience.
- Shanghai MicroPort MedBot's products are limited to surgical robots and related services.
- The firm's focus on minimally invasive surgery may restrict broader market expansion.
Opportunities
- Shanghai MicroPort MedBot's Honghu Orthopedic Surgical Robot targets growing orthopedic surgery demand.
- The company can expand its education and training services for surgical robots globally.
- Increasing demand for minimally invasive surgery in China presents growth potential.
Threats
- The surgical robot market faces competition from established medical device companies.
- Regulatory changes in China could impact surgical robot approvals.
- Shanghai MicroPort MedBot's reliance on Shanghai headquarters may limit international expansion.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.